Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-10004 for Vulvodynia
NCT00814632Phase 2Completed
- Start
- Dec 2008
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apremilast in vulvodynia. Primary endpoint: Global Response Assessment at 12 weeks. Started Dec 2008; status: completed.
02
Drugs
apremilast
03
Conditions
vulvodynia
Beyond the preview
Go deeper on NCT00814632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00814632.